アルツハイマー病治療の新たなストラテジー

出版社： 先端医学社
著者：
発行日： 2022-04-15
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784865505405
電子書籍版： 2022-04-15 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,950 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,465 円(税込)

購入する

商品紹介

アルツハイマー病(AD)の原因解明が進むなか、治療への新たなアプローチが試みられている。Aducanumabなどの疾患修飾薬の開発によりADの進行を遅らせる治療への入り口がわずかにみえてきた。そこで本書はADにのみフォーカスし、6つのテーマを網羅的にまとめたこれまでにない書物である。最先端の情報も数多く掲載されているので、エキスパートにも読みごたえが保証できる一冊になっている。

目次

  • Part 1　アルツハイマー病の現状と課題-わが国および世界の状況を含めて
    　1. 認知症の動向から探るアルツハイマー病の現状
    　2. アルツハイマー病における医療費・介護負担の現状と課題

    Part 2　アルツハイマー病の発症機序
    　1. アミロイドカスケード仮説からみたアルツハイマー病の病態機序
    　2. タウ蛋白質の病理形成と神経細胞死
    　3. 神経炎症からのアプローチ(ミクログリア、アストロサイト)
    　4. GWASによるアルツハイマー病関連遺伝子探索

    Part 3　アルツハイマー病の症候と診断
    　1．アルツハイマー病の症候と診断基準
    　2．疾患修飾薬を見据えた早期アルツハイマー病の診断（J-ADNI，J-TRCなどの観点から)
    　3．早期アルツハイマー病における神経心理と臨床診断
    　4-1．アルツハイマー病の早期診断に向けた画像検査　MRI
    　4-2．アルツハイマー病の早期診断に向けた画像検査　SPECTおよびFDG-PET
    　4-3．アルツハイマー病の早期診断に向けた画像検査　アミロイドPET
    　4-4．アルツハイマー病の早期診断に向けた画像検査　タウPET
    　5．アルツハイマー病の液性バイオマーカー
    　6．脳脊髄液検査における腰椎穿刺の手技とポイント

    Part 4　アルツハイマー病の治療と現状
    　1．アルツハイマー病の発症リスク低減
    　2．症状改善薬の位置づけと役割
    　3．BPSDへの対処方法
    　4．アルツハイマー病における多職種連携によるチーム医療
    　5．早期アルツハイマー病の告知と心理的影響

    Part 5　アルツハイマー病の新規治療-臨床的意義
    　1．疾患修飾薬の開発と現在（BACE 阻害薬などを含めて）
    　2．抗Aβ抗体（aducanumab，lecanemab，donanemab，gantenerumabなど）
    　3．抗タウ抗体
    　4．脳アミロイドアンギオパチーとアミロイド関連画像異常（ARIA）

    Part 6　アルツハイマー病診断・治療の新しい技術
    　1-1．AIを用いたアルツハイマー病の早期診断
    　　　　日常生活動作の解析による認知症の早期スクリーニング
    　1-2．AIを用いたアルツハイマー病の早期診断
    　　　　顔の解析による認知症の早期発見
    　2．iPS細胞を用いたアルツハイマー病研究・治療の新しい技術

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 アルツハイマー病の現状と課題 - わが国および世界の状況を含めて

P.5 掲載の参考文献
1) Muller U, Winter P, Graeber MB : A presenilin 1 mutation in the first case of Alzheimer's disease. Lancet Neurol 12 : 129-130, 2013
PubMed
2) Klunemann HH, Fronhofer W, Wurster H et al : Alzheimer's second patient : Johann F. and his family. Ann Neurol 52 : 520-523, 2002
 
3) Schottky J : Ober prasenile Verblodungen. Z Ges Neurol Psychiat 140 : 333-397, 1932
 
4) O'Neill A : Life expectancy (from birth) in Germany, from 1875 to 2020, 2019. https://www.statista.com/statistics/1041098/life-expectancy-germany-all-time/
 
5) 辻山義光 : 特発性脳委縮 : アルツハイメル病・ピック病・クロイツフェルト-ヤコブ病. 南江堂, 東京, 1963, pp1-40
 
6) DeTure MA, Dickson DW : The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener 14 : 32, 2019
 
7) 本間昭 : 老年精神医学-2000年を迎えて-. 老年精神医学雑誌 11 : 68-69, 2000
Medical*Online
8) Hardy J, Allsop D : Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12 : 383-388, 1991
 
9) Davies P, Maloney AJ : Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 : 1403, 1976
 
10) Mori E, Ikeda M, Kosaka K et al : Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled trial. Ann Neurol 72 : 41-52, 2012
PubMed
11) Ikeda M, Mori E, Matsuo K et al : Donepezil for dementia with Lewy bodies : a randomized placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther 7 : 4, 2015
PubMed
12) Jack CR Jr, Bennett DA, Blennow K et al : NIA-AA research framework : toward a biological definition of Alzheimer's disease. Alzheimers Dement 14 : 535-562, 2018
 
P.9 掲載の参考文献
1) 総務省統計局 : 高齢者人口. https://www.stat.go.jp/data/topics/topi1291.html
 
2) Christina Patterson : World Alzheimer Report 2018. https://www.alzint.org/resource/world-alzheimer-report-2018/
 
3) Wittenberg R, Knapp M, Hu B et al : The costs of dementia in England. Int J Geriatr Psychiatry 34 : 1095-1103, 2019
PubMed
4) Alzheimer's Association Report, 2021 Alzheimer's disease facts and figures. https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf
 
5) Cure Alzheimer's Fund. Stats & costs. https://curealz.org/the-disease/stats-and-costs/
 
6) Deb A, Thornton JD, Sambamoorthi U et al : Direct and indirect cost of managing Alzheimer's disease and related dementias in the United States. Expert Rev Pharmacoecon Outcomes Res 17 : 189-202, 2017
 
7) Sado M, Ninomiya A, Shikimoto R et al : The estimated cost of dementia in Japan, the most aged society in the world. PLoS One 13 : e0206508, 2018
PubMed
8) Ikeda S, Mimura M, Ikeda M et al : Economic burden of Alzheimer's disease dementia in Japan. J Alzheimers Dis 81 : 309-319, 2021
PubMed

Part 2 アルツハイマー病の発症機序

P.15 掲載の参考文献
1) Jack CR Jr, Knopman DS, Jagust WJ et al : Tracking pathophysiological processes in Alzheimer's disease : an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12 : 207-216, 2013
 
2) Selkoe DJ, Hardy J : The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8 : 595-608, 2016
PubMed
3) Tomita T, Iwatsubo T : Structural biology of presenilins and signal peptide peptidases. J Biol Chem 288 : 14673-14680, 2013
PubMed
4) Tarasoff-Conway JM, Carare RO, Osorio RS et al : Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 11 : 457-470, 2015
PubMed
5) Hellstrom-Lindahl E, Ravid R, Nordberg A : Age-dependent decline of neprilysin in Alzheimer's disease and normal brain : inverse correlation with Aβ levels. Neurobiol Aging 29 : 210-221, 2008
 
6) Sierksma A, Escott-Price V, De Strooper B : Translating genetic risk of Alzheimer's disease into mechanistic insight and drug targets. Science 370 : 61-66, 2020
PubMed
7) Cacace R, Sleegers K, Van Broeckhoven C : Molecular genetics of early-onset Alzheimer's disease revisited. Alzheimers Dement 12 : 733-748, 2016
PubMed
8) Xia Q, Yang X, Shi J et al : The protective A673T mutation of amyloid precursor protein (APP) in Alzheimer's disease. Mol Neurobiol 58 : 4038-4050, 2021
 
9) Cline EN, Bicca MA. Viola KL et al : The Aβ oligomer hypothesis : beginning of the third decade. J Alzheimers Dis 64 : S567-S610, 2018
 
10) Romoli M, Sen A, Parnetti L et al : Aβ : a potential link between epilepsy and cognitive decline. Nat Rev Neurol 17 : 469-485, 2021
 
11) Zott B, Busche MA, Sperling RA et al : What happens with the circuit in Alzheimer's disease in mice and humans? Annu Rev Neurosci 41 : 277-297, 2018
PubMed
12) Busche MA, Hyman BT : Synergy between Aβ and tau in Alzheimer's disease. Nat Neurosci 23 : 1183-1193, 2020
 
13) Braak H, Thal DR, Ghebremedhin E et al : Stages of the pathologic process in Alzheimer disease : age categories from 1 to 100 years. J Neuropathol Exp Neurol 70 : 960-969, 2011
PubMed
P.20 掲載の参考文献
1) McDade E, Bateman RJ : Stop Alzheimer's before it starts. Nature 547 : 153-155, 2017
 
2) Jonsson T, Atwal JK, Steinberg S et al : A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488 : 96-99, 2012
 
3) Pascoal TA, Benedet AL, Ashton NJ et al : Microglial activation and tau propagate jointly across Braak stages. Nat Med 27 : 1592-1599, 2021
PubMed
4) Clayton K, Delpech JC, Herron S et al : Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model. Mol Neurodegener 16 : 18, 2021
 
5) He Z, Guo JL, McBride JD et al : Aβ plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24 : 29-38, 2018
 
6) Saito T, Mihira N, Matsuba Y et al : Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation. J Biol Chem 294 : 12754-12765, 2019
PubMed
7) Taniguchi-Watanabe S, Arai T, Kametani F et al : Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol 131 : 267-280, 2016
PubMed
8) Hickman RA, Flowers XE, Wisniewski T : Primary age-related tauopathy (PART) : addressing the spectrum of neuronal tauopathic changes in the aging brain. Curr Neurol Neurosci Rep 20 : 39, 2020
PubMed
9) Saito T, Chiku T, Oka M et al : Disulfide bond formation in microtubule-associated tau protein promotes tau accumulation and toxicity in vivo. Hum Mol Genet 30 : 1955-1967, 2021
PubMed
10) Hashimoto S, Matsuba Y, Kamano N et al : Tau binding protein CAPON induces tau aggregation and neurodegeneration. Nat Commun 10 : 2394, 2019
PubMed
11) Moujalled D, Strasser A, Liddell JR : Molecular mechanisms of cell death in neurological diseases. Cell Death Differ 28 : 2029-2044, 2021
PubMed
12) Strasser A, O'Connor L, Dixit VM et al : Apoptosis signaling. Annu Rev Biochem 69 : 217-245, 2000
 
13) Yang Y, Klionsky DJ : Autophagy and disease : unanswered questions. Cell Death Differ 27 : 858-871, 2020
PubMed
14) Gleitze S, Paula-Lima A, Nunez MT et al : The calcium-iron connection in ferroptosis-mediated neuronal death. Free Radic Biol Med 175 : 28-41, 2021
PubMed
15) Ding J, Wang K, Liu W et al : Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535 : 111-116, 2016
PubMed
16) Salvadores N, Court FA : The necroptosis pathway and its role in age-related neurodegenerative diseases : will it open up new therapeutic avenues in the next decade? Expert Opin Ther Targets 24 : 679-693, 2020
PubMed
17) Fricker M, Tolkovsky AM, Borutaite V : Neuronal cell death. Physiol Rev 98 : 813-880, 2018
PubMed
18) Wightman DP, Jansen IE, Savage JE et al : A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 53 : 1276-1282, 2021
PubMed
P.25 掲載の参考文献
1) Knopman DS, Amieva H, Petersen RC et al : Alzheimer disease. Nat Rev Dis Primers 7 : 33, 2021
PubMed
2) Chen Y, Strickland MR, Soranno A et al : Apolipoprotein E : structural insights and links to Alzheimer disease pathogenesis. Neuron 109 : 205-221, 2021
PubMed
3) Chen Y, Colonna M : Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice? J Exp Med 218 : e20202717, 2021
 
4) Spanos F, Liddelow SA : An overview of astrocyte responses in genetically induced Alzheimer's disease mouse models. Cells 9 : 2415, 2020
 
5) Kikuchi K, Kidana K, Tatebe T et al : Dysregulated metabolism of the Aβ protein and therapeutic approaches in Alzheimer disease. J Cell Biochem 118 : 4183-4190, 2017
 
6) Ikeda T, Hori Y, Sohma Y et al : Photo-oxygenation : an innovative new therapeutic approach against amyloidoses. Adv Exp Med Biol 1339 : 415-422, 2021
PubMed
P.33 掲載の参考文献
1) Goate A, Chartier-Harlin MC, Mullan M et al : Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 : 704-706, 1991
PubMed
2) Schellenberg GD, Anderson L, O'dahl S et al : APP717, APP693, and PRIP gene mutations are rare in Alzheimer disease. Am J Hum Genet 49 : 511-517, 1991
 
3) Schellenberg GD, Bird TD, Wijsman EM et al : Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258 : 668-671, 1992
PubMed
4) Levy-Lahad E, Wijsman EM, Nemens E et al : A familial Alzheimer's disease locus on chromosome 1. Science 269 : 970-973, 1995
PubMed
5) Levy-Lahad E, Wasco W, Poorkaj P et al : Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 : 973-977, 1995
PubMed
6) de Rojas I, Moreno-Grau S, Tesi N et al : Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nat Commun 12 : 3417, 2021
 
7) Wightman DP, Jansen IE, Savage JE et al : A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 53 : 1276-1282, 2021
PubMed
8) Coon KD, Myers AJ, Craig DW et al : A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68 : 613-618, 2007
 
9) Asanomi Y, Shigemizu D, Miyashita A et al : A rare functional variant of SHARPIN attenuates the inflammatory response and associates with increased risk of late-onset Alzheimer's disease. Mol Med 25 : 20, 2019
PubMed
10) Miyashita A, Koike A, Jun G et al : SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS One 8 : e58618, 2013
PubMed
11) Hirano A, Ohara T, Takahashi A et al : A genome-wide association study of late-onset Alzheimer's disease in a Japanese population. Psychiatr Genet 25 : 139-146, 2015
 
12) Kang S, Gim J, Lee J et al : Potential novel genes for late-onset Alzheimer's disease in East-Asian descent identified by APOE-stratified genome-wide association study. J Alzheimers Dis 82 : 1451-1460, 2021
PubMed
13) Shigemizu D, Mitsumori R, Akiyama S et al : Ethnic and trans-ethnic genome-wide association studies identify new loci influencing Japanese Alzheimer's disease risk. Transl Psychiatry 11 : 151, 2021
PubMed
14) Park JH, Park I, Youm EM et al : Novel Alzheimer's disease risk variants identified based on whole-genome sequencing of APOE e4 carriers. Transl Psychiatry 11 : 296, 2021
PubMed
15) Zhou X, Chen Y, Mok KY et al : Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer's disease pathogenesis. Proc Natl Acad Sci U S A 115 : 1697-1706, 2018
PubMed
16) Jia L, Li F, Wei C et al : Prediction of Alzheimer's disease using multi-variants from a Chinese genome-wide association study. Brain 144 : 924-937, 2021
 
17) Strittmatter WJ, Saunders AM, Schmechel D et al : Apolipoprotein E : high-avidity binding to Aβ and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90 : 1977-1981, 1993
 
18) Strittmatter WJ, Weisgraber KH, Huang DY et al : Binding of human apolipoprotein E to synthetic Aβ peptide : isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90 : 8098-8102, 1993
 
19) Chartier-Harlin MC, Parfitt M, Legrain S et al : Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease : analysis of the 19q13.2 chromosomal region. Hum Mol Genet 3 : 569-574, 1994
PubMed
20) Rogaeva E, Meng Y, Lee JH et al : The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39 : 168-177, 2007
PubMed
21) Bertram L, Lange C, Mullin K et al : Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 83 : 623-632, 2008
PubMed
22) Lambert JC, Heath S, Even G et al : Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41 : 1094-1099, 2009
PubMed
23) Harold D, Abraham R, Hollingworth P et al : Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41 : 1088-1093, 2009
PubMed
24) Seshadri S, Fitzpatrick AL, Ikram MA et al : Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303 : 1832-1840, 2010
PubMed
25) Hollingworth P, Harold D, Sims R et al : Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43 : 429-435, 2011
PubMed
26) Jonsson T, Atwal JK, Steinberg S et al : A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488 : 96-99, 2012
 
27) Lambert JC, Ibrahim-Verbaas CA, Harold D et al : Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45 : 1452-1458, 2013
PubMed
28) Benitez BA, Jin SC, Guerreiro R et al : Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol Aging 35 : 1510.e19-1510.e26, 2014
 
29) Desikan RS, Schork AJ, Wang Y et al : Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol Psychiatry 20 : 1588-1595, 2015
PubMed
30) Desikan RS, Schork AJ, Wang Y et al : Polygenic overlap between C-reactive protein, plasma lipids, and Alzheimer disease. Circulation 131 : 2061-2069, 2015
PubMed
31) Jun G, Ibrahim-Verbaas CA, Vronskaya M et al : A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry 21 : 108-117, 2016
PubMed
32) Nicolas G, Charbonnier C, Wallon D et al : SORL1 rare variants : a major risk factor for familial early-onset Alzheimer's disease. Mol Psychiatry 21 : 831-836, 2016
 
33) Sims R, van der Lee SJ, Naj AC et al : Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49 : 1373-1384, 2017
PubMed
34) Marioni RE, Harris SE, Zhang Q et al : GWAS on family history of Alzheimer's disease. Transl Psychiatry 8 : 99, 2018
PubMed
35) Kunkle BW, Grenier-Boley B, Sims R et al : Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet 51 : 414-430, 2019
 
36) Jansen IE, Savage JE, Watanabe K et al : Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat Genet 51 : 404-413, 2019
PubMed
37) Broce IJ, Tan CH, Fan CC et al : Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. Acta Neuropathol 137 : 209-226, 2019
PubMed
38) Van Acker ZP, Bretou M, Annaert W : Endo-lysosomal dysregulations and late-onset Alzheimer's disease : impact of genetic risk factors. Mol Neurodegener 14 : 20, 2019
PubMed
39) Kim HR, Jung SH, Kim J et al : Identifying novel genetic variants for brain amyloid deposition : a genome-wide association study in the Korean Population. Alzheimers Res Ther 13 : 117, 2021
PubMed

Part 3 アルツハイマー病の症候と診断

P.39 掲載の参考文献
1) McKhann G, Drachman D, Folstein M et al : Clinical diagnosis of Alzheimer's disease : report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 34 : 939-944, 1984
 
2) Jack CR Jr, Albert MS, Knopman DS et al : Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 : 257-262, 2011
 
3) Dubois B, Feldman HH, Jacova C et al : Advancing research diagnostic criteria for Alzheimer's disease : the IWG-2 criteria. Lancet Neurol 13 : 614-629, 2014
PubMed
4) Sperling RA, Aisen PS, Beckett LA et al : Toward defining the preclinical stages of Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 : 280-292, 2011
PubMed
5) Jack CR Jr, Bennett DA, Blennow K et al : NIA-AA Research Framework : toward a biological definition of Alzheimer's disease. Alzheimers Dement 14 : 535-562, 2018
 
6) Ebenau JL, Timmers T, Wesselman LMP et al : ATN classification and clinical progression in subjective cognitive decline : the SCIENCe project. Neurology 95 : e46-e58, 2020
PubMed
7) Soldan A, Pettigrew C, Fagan AM et al : ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology 92 : e1567-e1579, 2019
PubMed
8) Arriagada PV, Growdon JH, Hedley-Whyte ET et al : Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42 : 631-639, 1992
 
9) Braak H, Braak E : Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82 : 239-259, 1991
PubMed
10) Graff-Radford J, Yong KXX, Apostolova LG et al : New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurol 20 : 222-234, 2021
 
11) Ferreira D, Nordberg A, Westman E : Biological subtypes of Alzheimer disease : a systematic review and meta-analysis. Neurology 94 : 436-448, 2020
PubMed
12) Ferreira D, Verhagen C, Hernandez-Cabrera JA et al : Distinct subtypes of Alzheimer's disease based on patterns of brain atrophy : longitudinal trajectories and clinical applications. Sci Rep 7 : 46263, 2017
 
13) Ossenkoppele R, Lyoo CH, Sudre CH et al : Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. Alzheimers Dement 16 : 335-344, 2020
PubMed
14) Vogel JW, Young AL, Oxtoby NP et al : Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nat Med 27 : 871-888, 2021
PubMed
P.43 掲載の参考文献
1) WHO : https://www.who.int/news-room/fact-sheets/detail/dementia
 
2) 朝田隆 : 都市部における認知症有病率と認知症の生活機能障害への対応 平成24年度 厚生労働科学研究費補助金認知症対策総合研究事業・総括・分担研究報告書, 2013
 
3) 2021 Alzheimer's disease facts and figures. Alzheimers Dement 17 : 327-406, 2021
PubMed
4) ADI : Dementia statistics. https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
 
5) Ikeda S, Mimura M, Ikeda M et al : Economic burden of Alzheimer disease dementia in Japan. J Alzheimers Dis 81 : 309-319, 2021
PubMed
6) Senda M, Ishii K, Ito K et al : A Japanese multicenter study on PET and other biomarkers for subjects with potential preclinical and prodromal Alzheimer's disease. J Prev Alzheimers Dis 8 : 495-502, 2021
 
7) J-TRC : https://www.j-trc.org/ja/welcome
 
8) 佐藤謙一郎, 岩坪威 : ウェブ上での簡単なテストで, アルツハイマー病の前駆状態に該当する可能性を予測するアルゴリズムを開発. https://www.m.u-tokyo.ac.jp/news/admin/release_20210324.pdf, 2021
 
P.47 掲載の参考文献
1) 森悦朗 : 認知症に対する認知機能検査の現状と将来. 医学のあゆみ 257 : 403-409, 2016
Medical*Online
2) Mori E, Hirono N, Yamashita H et al : Premorbid brain size as a determinant of reserve capacity against intellectual decline in Alzheimer's disease. Am J Psychiatry 154 : 18-24, 1997
 
3) Nelson ME, Jester DJ, Petkus AJ et al : Cognitive reserve, Alzheimer's neuropathology, and risk of dementia : a systematic review and meta-analysis. Neuropsychol Rev 31 : 233-250, 2021
 
4) Folstein MF, Folstein SE, McHugh PR : "Mini-mental state" : a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 : 189-198, 1975
 
5) 森悦朗, 三谷洋子, 山鳥重 : 神経疾患患者における日本語版 Mini-Mental Stateテストの有用性. 神経心理学 1 : 82-90, 1985
 
6) Breton A, Casey D, Arnaoutoglou NA : Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia : meta-analysis of diagnostic accuracy studies. Int J Geriatr Psychiatry 34 : 233-242, 2019
PubMed
7) 加藤伸司, 下垣光, 小野寺敦志ほか : 改訂長谷川式簡易知能評価スケール (HDS-R) の作成. 老年精神医学雑誌 2 : 1339-1347, 1991
Medical*Online
8) Tsoi KK, Chan JY, Hirai HW et al : Cognitive tests to detect dementia : a systematic review and meta-analysis. JAMA Intern Med 175 : 1450-1458, 2015
PubMed
9) Tsoi KKF, Chan JYC, Hirai HW et al : Recall tests are effective to detect mild cognitive impairment : a systematic review and meta-analysis of 108 diagnostic studies. J Am Med Dir Assoc 18 : 807.e17-807.e29, 2017
 
10) Nasreddine ZS, Phillips NA, Bedirian V et al : The Montreal cognitive assessment, MoCA : a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53 : 695-699, 2005
 
11) 鈴木宏幸, 藤原佳典 : Montreal Cognitive Assessment (MoCA) の日本語版作成とその有効性について. 老年精神医学雑誌 21 : 198-202, 2010
Medical*Online
12) Pinto TCC, Machado L, Bulgacov TM et al : Is the Montreal cognitive assessment (MoCA) screening superior to the mini-mental state examination (MMSE) in the detection of mild cognitive impairment (MCI) and Aizheimer's disease (AD) in the elderly? Int Psychogeriatr 31 : 491-504, 2019
 
13) Mioshi E, Dawson K, Mitchell J et al : The Addenbrooke's cognitive examination revised (ACE-R) : a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 21 : 1078-1085, 2006
 
14) Dos Santos Kawata KH, Hashimoto R, Nishio Y et al : A validation study of the Japanese version of the Addenbrooke's cognitive examination-Revised. Dement Geriatr Cogn Dis Extra 2 : 29-37, 2012
PubMed
15) Hsieh S, Schubert S, Hoon C et al : Validation of the Addenbrooke's cognitive examination III in frontotemporal dementia and Alzheimer's disease. Dement Geriatr Cogn Disord 36 : 242-250, 2013
 
16) Mohs RC, Knopman D, Petersen RC et al : Development of cognitive instruments for use in clinical trials of antidementia drugs : additions to the Alzheimer's disease assessment scale that broaden its scope. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 11 (Suppl 2) : S13-S21, 1997
 
17) 本間昭, 福沢一吉, 塚田良雄ほか : Alzheimer's Disease Assessment Scale (ADAS) 日本版の作成. 老年精神医学雑誌 3 : 647-655, 1992
Medical*Online
18) 山下光, 博野信次, 池尻義隆ほか : Alzheimer's Disease Assessment Scale 日本版 (ADAS-J cog) の有用性の検討. 老年精神医学雑誌 9 : 187-194, 1998
Medical*Online
P.53 掲載の参考文献
1) Ferreira LK, Diniz BS, Forlenza OV et al : Neurostructural predictors of Alzheimer's disease : a meta-analysis of VBM studies. Neurobiol Aging 32 : 1733-1741, 2011
PubMed
2) Chua TC, Wen W, Slavin MJ et al : Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease : a review. Curr Opin Neurol 21 : 83-92, 2008
 
3) Nedergaard M : Neuroscience. Garbage truck of the brain. Science 340 : 1529-1530, 2013
PubMed
4) Taoka T, Masutani Y, Kawai H et al : Evaluation of glymphatic system activity with the diffusion MR technique : diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer's disease cases. Jpn J Radiol 35 : 172-178, 2017
 
5) Moon WJ, Lim C, Ha IH et al : Hippocampal blood-brain barrier permeability is related to the APOE4 mutation status of elderly individuals without dementia. J Cereb Blood Flow Metab 41 : 1351-1361, 2021
 
6) Ibrahim B, Suppiah S, Ibrahim N et al : Diagnostic power of resting-state fMRI for detection of network connectivity in Alzheimer's disease and mild cognitive impairment : a systematic review. Hum Brain Mapp 42 : 2941-2968, 2021
PubMed
7) Acosta-Cabronero J, Williams GB, Cardenas-Blanco A et al : In vivo quantitative susceptibility mapping (QSM) in Alzheimer's disease. PLoS One 8 : e81093, 2013
 
8) Kudo K, Harada T, Kameda H et al : Indirect proton MR imaging and kinetic analysis of 17O-labeled water tracer in the brain. Magn Reson Med Sci 17 : 223-230, 2018
PubMed
9) Silva I, Silva J, Ferreira R et al : Glymphatic system, AQP4, and their implications in Alzheimer's disease. Neurol Res Pract 3 : 5, 2021
 
10) Chen L, Liu J, Chu C et al : Deuterium oxide as a contrast medium for real-time MRI-guided endovascular neurointervention. Theranostics 11 : 6240-6250, 2021
PubMed
11) Alshuhri MS, Gallagher L, Work LM et al : Direct imaging of glymphatic transport using H2 17O MRI. JCI Insight 6 : e141159, 2021
 
P.58 掲載の参考文献
Ferrando R, Damian A : Brain SPECT as a biomarker of neurodegeneration in dementia in the era of molecular imaging : still a valid option? Front Neurol 12 : 629442, 2021
 
Smailagic N, Lafortune L, Kelly S et al : 18F-FDG PET for prediction of conversion to Alzheimer's disease dementia in people with mild cognitive impairment : an updated systematic review of test accuracy. J Alzheimers Dis 64 : 1175-1194, 2018
PubMed
石井一成 : 認知症のSPECT/PET診断-FDG-PETの保険適応に向けて. 臨床放射線 63 : 151-156, 2018
 
P.64 掲載の参考文献
1) Clark CM, Pontecorvo MJ, Beach TG et al : Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic Aβ plaques : a prospective cohort study. Lancet Neurol 11 : 669-678, 2012
 
2) Curtis C, Gamez JE, Singh U et al : Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol 72 : 287-294, 2015
PubMed
3) Sabri O, Sabbagh MN, Seibyl J et al : Florbetaben PET imaging to detect Aβ plaques in Alzheimer's disease : phase 3 study. Alzheimers Dement 11 : 964-974, 2015
 
4) 認知症性疾患診療ガイドライン, 日本神経学会監修, 「認知症疾患診療ガイドライン」作成委員会編. 医学書院, 東京, 2017
 
5) Klunk WE, Engler H, Nordberg A et al : Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 : 306-319, 2004
PubMed
6) Mintun MA, Larossa GN, Sheline YI et al : [11C] PIB in a nondemented population : potential antecedent marker of Alzheimer disease. Neurology 67 : 446-452, 2006
 
7) Jack CR Jr, Lowe VJ, Senjem ML et al : 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131 : 665-680, 2008
PubMed
8) Mormino EC, Kluth JT, Madison CM et al : Episodic memory loss is related to hippocampal-mediated Aβ deposition in elderly subjects. Brain 132 : 1310-1323, 2009
 
9) Rowe CC, Bourgeat P, Ellis KA et al : Predicting Alzheimer disease with Aβ imaging : results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 74 : 905-913, 2013
 
10) Farrer LA, Cupples LA, Haines JL et al : Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA 278 : 1349-1356, 1997
PubMed
11) Rowe CC, Ellis KA, Rimajova M et al : Amyloid imaging results from the Australian imaging, biomarkers and lifestyle (AIBL) study of aging. Neurobiol Aging 31 : 1275-1283, 2010
PubMed
12) Reiman EM, Chen K, Liu X et al : Fibrillar Aβ burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106 : 6820-6825, 2009
 
13) Morris JC, Roe CM, Xiong C et al : APOE predicts Aβ but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67 : 122-131, 2010
 
14) Jansen WJ, Ossenkoppele R, Knol DL et al : Prevalence of cerebral amyloid pathology in persons without dementia : a meta-analysis. JAMA 313 : 1924-1938, 2015
PubMed
15) Ossenkoppele R, Jansen WJ, Rabinovici GD et al : Prevalence of amyloid PET positivity in dementia syndromes : a meta-analysis. JAMA 313 : 1939-1949, 2015
PubMed
16) Su Y, Flores S, Wang G et al : Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. Alzheimers Dement (Amst) 11 : 180-190, 2019
PubMed
17) Klunk WE, Price JC, Mathis CA et al : Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27 : 6174-6184, 2007
PubMed
18) Rowe CC, Pejoska S, Mulligan RS et al : Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for Aβ imaging in aging and dementia. J Nucl Med 54 : 880-886, 2013
 
19) Villemagne VL, Burnham S, Bourgeat P et al : Aβ deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease : a prospective cohort study. Lancet Neurol 12 : 357-367, 2013
 
20) Farrar G, Molinuevo JL, Zanette M et al : Is there a difference in regional read [18F] flutemetamol amyloid patterns between end-of-life subjects and those with amnestic mild cognitive impairment? Eur J Nucl Med Mol Imaging 46 : 1299-1308, 2019
 
21) Klunk WE, Koeppe RA, Price JC et al : The centiloid project : standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11 : 1-15.e1-4, 2015
 
22) La Joie R, Ayakta N, Seeley WW et al : Multisite study of the relationships between antemortem [11C] PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement 15 : 205-216, 2019
PubMed
23) アミロイドPETイメージング剤の適正使用ガイドライン, 日本核医学会, 日本認知症学会, 日本神経学会編, 2017. http://jsnm.org/archives/655/
 
24) Barthel H, Sabri O : Clinical use and utility of amyloid imaging. J Nucl Med 58 : 1711-1717, 2017
PubMed
25) Rabinovici GD, Gatsonis C, Apgar C et al : Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with miid cognitive impairment or dementia. JAMA 321 : 1286-1294, 2019
PubMed
26) Hornberger J, Bae J, Watson I et al : Clinical and cost implications of Aβ detection with Aβ positron emission tomography imaging in early Alzheimer's disease-the case of florbetapir. Curr Med Res Opin 33 : 675-685, 2017
 
27) Jack CR Jr, Bennett DA, Blennow K et al : NIA-AA research framework : toward a biological definition of Alzheimer's disease. Alzheimers Dement 14 : 535-562, 2018
 
28) Caroli A, Prestia A, Galluzzi S et al : Mild cognitive impairment with suspected nonamyloid pathology (SNAP) : prediction of progression. Neurology 84 : 508-515, 2015
PubMed
P.71 掲載の参考文献
1) Leuzy A, Chiotis K, Lemoine L et al : Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry 24 : 1112-1134, 2019
 
2) Tagai K, Ono M, Kubota M et al : High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's disease tauopathies. Neuron 109 : 42-58.e8, 2021
 
3) Wolters EE, Dodich A, Boccardi M et al : Clinical validity of increased cortical uptake of [18F] flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging 48 : 2097-2109, 2021
PubMed
4) Bucci M, Chiotis K, Nordberg A : Alzheimer's disease profiled by fluid and imaging markers : tau PET best predicts cognitive decline. Mol Psychiatry, 2021. Online ahead of print
 
5) Vogel JW, Young AL, Oxtoby NP et al : Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nat Med 27 : 871-881, 2021
PubMed
P.77 掲載の参考文献
1) Jack CR Jr, Bennett DA, Biennow K et al : NIA-AA research framework : toward a biological definition of Alzheimer's disease. Alzheimers Dement 14 : 535-562, 2018
 
2) Patterson BW, Elbert DL, Mawuenyega KG et al : Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol 78 : 439-453, 2015
PubMed
3) Sato C, Barthelemy NR, Mawuenyega KG et al : Tau kinetics in neurons and the human central nervous system. Neuron 98 : 1284-1298.e7, 2018
 
4) Janelidze S, Stomrud E, Smith R et al : Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nat Commun 11 : 1683, 2020
 
5) Barthelemy NR, Li Y, Joseph-Mathurin N et al : A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med 26 : 398-407, 2020
PubMed
6) ALZBIOMARKER : https://www.alzforum.org/alzbiomarker
PubMed
7) Schindler SE, Bollinger JG, Ovod V et al : High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 93 : e1647-e1659, 2019
 
8) Verberk IMW, Slot RE, Verfaillie SCJ et al : Plasma amyloid as prescreener for the earliest Alzheimer pathological changes. Ann Neurol 84 : 648-658, 2018
PubMed
9) Thijssen EH, La Joie R, Strom A et al : Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration : a retrospective diagnostic performance study. Lancet Neurol 20 : 739-752, 2021
PubMed
10) Disanto G, Barro C, Benkert P et al : Serum neurofilament light : a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81 : 857-870, 2017
 
11) Aduhelm Prescribing Information : https://www.biogencdn.com/us/aduhelm-pi.pdf
 
12) Cummings JL, Cohen S, van Dyck CH et al : ABBY : a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology 90 : e1889-e1897, 2018
 
13) Doody RS, Thomas RG, Farlow M et al : Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370 : 311-321, 2014
PubMed
14) Egan MF, Kost J. Tariot PN et al : Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. N Engl J Med 378 : 1691-1703, 2018
PubMed
15) Egan MF, Kost J, Voss T et al : Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med 380 : 1408-1420, 2019
PubMed
16) Honig LS, Vellas B, Woodward M et al : Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med 378 : 321-330, 2018
PubMed
17) Ostrowitzki S, Lasser RA, Dorflinger E et al : A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther 9 : 95, 2017
 
18) Salloway S, Farlow M, McDade E et al : A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med 27 : 1187-1196, 2021
PubMed
19) Salloway S, Sperling R, Brashear HR : Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med 370 : 1460, 2014
 
20) Sperling R, Henley D, Aisen PS et al : Findings of efficacy, safety, and biomarker outcomes of atabecestat in prechnical Alzheimer disease : a truncated randomized phase 2b/3 clinical trial. JAMA Neurol 78 : 293-301, 2021
PubMed
21) Swanson CJ, Zhang Y, Dhadda S et al : A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 13 : 80, 2021
 
22) Wessels AM, Tariot PN, Zimmer JA et al : Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease : the AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol 77 : 199-209, 2020
PubMed
23) Yang T, Dang Y, Ostaszewski B et al : Target engagement in an alzheimer trial : crenezumab lowers Aβ oligomers in cerebrospinal fluid. Ann Neurol 86 : 215-224, 2019
 
24) Witbracht MG, Bernstein OM, Lin V et al : Education and message framing increase willingness to undergo research lumbar puncture : a randomized controlled trial. Front Med (Lausanne) 7 : 493, 2020
PubMed
25) Cummings J, Aisen P, Apostolova LG et al : Aducanumab : appropriate use recommendations. J Prev Alzheimers Dis, 2021, In Press
 
P.82 掲載の参考文献
Johnson KS, Sexton DJ : Lumbar puncture : technique, indications, contraindications, and complications in adults. UpToDate, 2021
 
Costerus JM, Matthijs CB, van de Beek D : Technological advances and changing indications for lumbar puncture in neurological disorders. Lancet Neurol 17 : 268-278, 2018
 
Wright BL, Lai JT, Sinclair AJ : Cerebrospinal fluid and lumbar puncture : a practical review. J Neurol 259 : 1530-1545, 2012
PubMed
Arevalo-Rodriguez I, Ciapponi A, Roque i Figuls M et al : Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev 3 : CD009199, 2016
PubMed

Part 4 アルツハイマー病の治療と現状

P.88 掲載の参考文献
1) 坂田智子, 二宮利治, 清原裕 : 高血圧と認知症予防. 神経治療学 32 : 905-910, 2015
Medical*Online
2) 令和元年度 厚生労働省老人保健健康増進等事業. 海外認知症予防ガイドラインの整理に関する調査研究事業 WHOガイドライン「認知機能低下及び認知症のリスク低減」邦訳検討委員会
 
3) Ninomiya T : Diabetes mellitus and dementia. Curr Diab Rep 14 : 487, 2014
PubMed
4) Chu CS, Tseng PT, Stubbs B et al : Use of statins and the risk of dementia and mild cognitive impairment : a systematic review and meta-analysis. Sci Rep 8 : 5804, 2018
PubMed
5) Ohara T, Ninomiya T, Hata J et al : Midlife and late-life smoking and risk of dementia in the community : the Hisayama study. J Am Geriatr Soc 63 : 2332-2339, 2015
PubMed
6) Anstey KJ, Mack HA, Cherbuin N : Alcohol consumption as a risk factor for dementia and cognitive decline : meta-analysis of prospective studies. Am J Geriatr Psychiatry 17 : 542-555, 2009
PubMed
7) Xu W, Wang H, Wan Y et al : Alcohol consumption and dementia risk : a dose-response meta-analysis of prospective studies. Eur J Epidemiol 32 : 31-42, 2017
 
8) Hamer M, Chida Y : Physical activity and risk of neurodegenerative disease : a systematic review of prospective evidence. Psychol Med 39 : 3-11, 2009
PubMed
9) Ozawa M, Ninomiya T, Ohara T et al : Dietary patterns and risk of dementia in an elderly Japanese population : the Hisayama study. Am J Clin Nutr 97 : 1076-1082, 2013
 
P.92 掲載の参考文献
1) CQ6-7 Alzheimer型認知症の薬物療法と治療アルゴリズムは何か. 認知症疾患診療ガイドライン 2017, 日本神経学会監修, 「認知症疾患診療ガイドライン」作成委員会編集, 医学書院, 東京, pp224-229, 2017
 
2) Matsunaga S, Fujishiro H, Takechi H : Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment : a systematic review and meta-analysis. J Alzheimers Dis 71 : 513-523, 2019
PubMed
P.96 掲載の参考文献
1) 水上勝義 : すぐに役立つBPSD薬物療法ハンドブック, 医学と看護社, 東京, 2020
 
2) Hart DJ, Craig D, Compton SA et al : A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease. Int J Geriatr Psychiatry 18 : 1037-1042, 2003
PubMed
3) 高齢者の安全な薬物療法ガイドライン, 日本老年医学会編, メジカルビュー, 東京, 2015
 
4) the 2019 American Geriatrics Society Beers Criteria(R) Update Expert Panel : American Geriatrics Society 2019 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc 67 : 674-694, 2019
 
5) 認知症疾患診療ガイドライン 2017, 日本神経学会監修, 「認知症疾患診療ガイドライン」作成委員会編, 医学書院, 東京, 2017
 
6) McCleery J, Sharpley AL : Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst Rev 11 : CD009178, 2020
PubMed
7) Matsuda Y, Kishi T, Shibayama H et al : Yokukansan in the treatment of behavioral and psychological symptoms of dementia : a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 28 : 80-86, 2013
PubMed
8) 厚生労働省 : かかりつけ医のためのBPSDに対応する向精神薬使用ガイドライン (第2版), 2018. https://www.mhlw.go.jp/file/06-Seisakujouhou-12300000-Roukenkyoku/0000140619.pdf
 
9) 厚生労働省 : 高齢者の医薬品適正使用の指針 総論編, 2018. https://www.mhlw.go.jp/file/04-Houdouhappyou-11125000-Iyakushokuhinkyoku-Anzentaisakuka/0000209385.pdf
 
10) 厚生労働省 : 高齢者の医薬品適正使用の指針 各論編 (療養環境別), 2019, https://www.mhlw.go.jp/content/11120000/000568037.pdf
 
P.101 掲載の参考文献
1) 埼玉県立大学 (編集) : IPWを学ぶ-利用者中心の保健医療福祉連携. 中央法規出版, 東京, 2009
 
P.104 掲載の参考文献
1) 繁田雅弘, 半田幸子, 今井幸充 : 「認知症診療における適切な情報提供と対応」～患者と家族の安心と納得を左右する要因～調査結果報告書 平成22年度首都大学東京傾斜的研究費 (部局分) 健康福祉学部部局競争的経費, 2011. https://tokyo-metro-u.repo.nii.ac.jp/?action=repository_uri&item_id=4231&file_id=18&file_no=1
 
2) 繁田雅弘 : II 認知症の人と家族を支える説明 3. 本人に対する病気の説明 : 告知. 実践 認知症診療 認知症の人と家族・介護者を支える説明, 繁田雅弘編, 医薬ジャーナル社, 東京, pp45-48, 2013
 
3) 繁田雅弘, 半田幸子, 今井幸充 : ケアラーへの情報提供-医療機関の情報提供に対する家族の満足度調査から-. 老年精神医学誌 25 : 984-992, 2014
 
4) World Health Organization : Ensuring a human rights-based approach for people living with dementia, 2015. https://www.who.int/mental_health/neurology/dementia/dementia_thematicbrief_human_rights.pdf
 
5) National Institute for Health and Care Excellence : Dementia : assessment, management and support for people living with dementia and their carers, 2018. https://www.nice.org.uk/guidance/ng97
 
6) Starkstein SE, Jorge R, Mizrahi R et al : A diagnostic formulation for anosognosia in Alzheimer's disease. J Neurol Neurosurg Psychiatry 77 : 719-725, 2006
 
7) Wright BA : Physical disability-a psychological approach. Harper & Row, NewYork, 1960
 
8) McGowin DF : Living in the labyrinth, Elder Books, 私が壊れる瞬間 アルツハイマー病患者の手記, 中村洋子訳, ディーエイチシー, 東京, 1993
 
9) Bryden C : Dancing with dementia My story of living positively with dementia. Jessica Kingsley Publishers, London and Philadelphia, 2005, 私はわたしになっていく 認知症とダンスを 改訂新版, 馬籠久美子, 桧垣陽子訳, クリエイツかもがわ, 京都, 2012
 

Part 5 アルツハイマー病の新規治療 - 臨床的意義

P.112 掲載の参考文献
1) 2021 Alzheimer's facts and figures. Alzheimer's Association, Alzheimers Dement 17 : 327-406, 2021
PubMed
2) Cummings J, Lee G, Zhong K et al : Alzheimer's disease drug development pipeline : 2021. Alzheimers Dement 7 : e12179, 2021
PubMed
3) Muhs A, Hickman DT, Pihlgren M et al : Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci U S A 104 : 9810-9815, 2007
PubMed
4) Winblad B, Andreasen N, Minthon L et al : Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease : randomized, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11 : 597-604, 2012
 
5) Farlow MR, Andreasen N, Riviere ME et al : Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther 7 : 23, 2015
 
6) Doody RS, Raman R, Farlow M et al : A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 369 : 341-350, 2013
PubMed
7) Coric V, van Dyck CH, Salloway S et al : Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69 : 1430-1440, 2012
 
8) Hu X, Hicks CW, He W et al : Bacel modulates myelination in the central and peripheral nervous system. Nat Neurosci 9 : 1520-1525, 2006
 
9) Willem M, Garratt AN, Novak B et al : Control of peripheral nerve myelination by the β-secretase BACE1. Science 314 : 664-666, 2006
 
10) Forman M, Tseng J, Palcza J et al : The novel BACE inhibitor MK-8931 dramatically lowers CSF a peptides in healthy subjects : results from a rising single dose study (PL02.004). Neurology 78 (1 suppl) : PL02.004, 2012
 
11) Forman M, Kleijn HJ, Oockendorf MF et al : The novel BACE inhibitor MK-8931 dramatically lowers CSF Aβ in patients with mild-to-moderate Alzheimer's disease. Alzheimers Dement 9 : P139, 2013
 
12) Egan MF, Kost J, Tariot PN et al : Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. A Engl J Med 378 : 1691-1703, 2018
 
13) Egan MF, Kost J, Voss T et al : Randomized trial of verubecestat for prodromal Alzheimer's disease. N Engl J Med 380 : 1408-1420, 2019
PubMed
14) Braak H, Braak E : Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl 165 : 3-12, 1996
PubMed
15) Gauthier S, Feldman HH, Schneider LS et al : Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or mpderate Alzheimer's disease : a randomized, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388 : 2873-2884, 2016
PubMed
16) Novak P, Schmidt R, Kontsekova E et al : Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease : a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16 : 123-134, 2017
 
17) Novak P, Kovacech B, Katina S et al : ADAMANT : a placebo-controlled randomized phase 2 study of A A Dvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nat Aging 1 : 521-534, 2021
 
18) Hickman DT, Lopez-Deber MP, Ndao DM et al : Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem 286 : 13966-13976, 2011
PubMed
19) Theunis C, Crespo-Biel N, Gafner V et al : Efficacy and safety of a liposome-based vaccine against protein tau, assessed in tau. P301L mice that model tauopathy. PLoS One 8 : e72301, 2013
PubMed
20) Appleby BS, Nacopoulos D, Milano N et al : A review : treatment of Alzheimer's disease discovered in repurposed agents. Dement Geriatr Cogn Disord 35 : 1-22, 2013
 
P.116 掲載の参考文献
1) Food and Drug Administration : FDA grants accelerated approval for Alzheimer's drug. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
 
2) Ferrero J, Williams L, Stella H et al : First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease. Alzheimers Dement (NY) 2 : 169-176, 2016
 
3) Linse S, Scheidt T, Bernfur K et al : Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies. Nat Struct Mol Biol 27 : 1125-1133, 2020
 
4) Food and Drug Administration : Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) meeting. https://www.fda.gov/media/145691/download
 
5) Sollvander S, Nikitidou E, Gallasch L et al : The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death. J Neuroinflammation 15 : 98, 2018
 
6) Lord A, Gumucio A, Englund H et al : An Aβ protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiol Dis 36 : 425-434, 2009
 
7) Swanson CJ, Zhang Y, Dhadda S et al : A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther 13 : 80, 2021
 
8) Demattos RB, Lu J, Tang Y et al : A plaque-specific antibody clears existing Aβ plaques in Alzheimer's disease mice. Neuron 76 : 908-920, 2012
 
9) Mintun MA, Lo AC, Duggan Evans C et al : Donanemab in early Alzheimer's disease. N Engl J Med 384 : 1691-1704, 2021
PubMed
10) Salloway S, Farlow M, McDade E et al : A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nat Med 27 : 1187-1196, 2021
PubMed
11) Food and Drug Administration : Aducanumab (marketed as Aduhelm) information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s003lbl.pdf
 
P.121 掲載の参考文献
1) 武田朱公 : タウ伝播仮説の可能性と限界について. 実験医学 35 : 2136-2141, 2017
Medical*Online
2) Takeda S : Tau propagation as a diagnostic and therapeutic target for dementia : potentials and unanswered questions. Front Neurosci 13 : 1274, 2019
PubMed
3) Lewis J, Dickson DW : Propagation of tau pathology : hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol 131 : 27-48, 2016
PubMed
4) Walker LC, Diamond MI, Duff KE et al : Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 70, 304-310, 2013
PubMed
5) 武田朱公 : タウ伝播を標的とした治療法開発. 医学のあゆみ 273 : 23-27, 2020
Medical*Online
6) Dujardin S, Hyman BT : Tau prion-like propagation : state of the art and current challenges. Adv Exp Med Biol 1184 : 305-325, 2019
PubMed
7) Pedersen JT, Sigurdsson EM : Tau immunotherapy for Alzheimer's disease. Trends Mol Med 21, 394-402, 2015
PubMed
8) 武田朱公 : 認知症の進行を規定する因子の解析と診断・治療法への応用. Dementia Jpn 35 : 427-434, 2021
 
9) Dujardin S, Commins C, Lathuiliere A et al : Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. Nat Med 26, 1256-1263, 2020
PubMed
10) Wesseling H, Mair W, Kumar M et al : Tau PTM profiles identify patient heterogeneity and stages of Alzheimer's disease. Cell 183, 1699-1713.e13, 2020
 
P.125 掲載の参考文献
1) Sperling RA, Jack CR, Black SE et al : Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials : recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 7 : 367-385, 2011
 
2) DiFrancesco JC, Longoni M, Piazza F : Anti-Aβ autoantibodies in amyloid related imaging abnormalities (ARIA) : candidate biomarker for immunotherapy in Alzheimer's disease and cerebral amyloid angiopathy. Front Neurol 6 : 207, 2015
 
3) Antolini L, DiFrancesco JC, Zedde M et al : Spontaneous ARIA-like events in cerebral amyloid angiopathy-related inflammation : a multicenter prospective longitudinal cohort study. Neurology 97 : e1809-e1822, 2021
PubMed

Part 6 アルツハイマー病診断・治療の新しい技術

P.131 掲載の参考文献
1) Ngandu T, Lehtisalo J, Solomon A et al : A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER) : a randomised controlled trial. Lancet 385 : 2255-2263, 2015
 
2) Servick K : Alzheimer's drug approved despite murky results. Science 372 : 1141, 2021
 
3) Kawa J, Bednorz A, Stepien P et al : Spatial and dynamical handwriting analysis in mild cognitive impairment. Comput Biol Med 82 : 21-28, 2017
PubMed
4) Mc Ardle R, Galna B, Donaghy P et al : Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait? Alzheimers Dement 15 : 1367-1377, 2019
PubMed
5) Roark B, Mitchell M, Hosom JP et al : Spoken language derived measures for detecting mild cognitive impairment. IEEE Trans Audio Speech Lang process 19 : 2081-2090, 2011
 
6) Mielke MM, Roberts RO, Savica R et al : Assessing the temporal relationship between cognition and gait : slow gait predicts cognitive decline in the Mayo clinic study of aging. J Gerontol A Biol Sci Med Sci 68 : 929-937, 2013
 
7) Mueller KD, Koscik RL, Hermann BP et al : Declines in connected language are associated with very early mild cognitive impairment : results from the Wisconsin registry for Alzheimer's prevention. Front Aging Neurosci 9 : 437, 2018
 
8) VanSwearingen JM, Paschal KA, Bonino P et al : The modified gait abnormality rating scale for recognizing the risk of recurrent falls in community-dwelling elderly adults. Phys Ther 76 : 994-1002, 1996
PubMed
9) Yamada Y, Shinkawa K, Kobayashi M et al : Combining multimodal behavioral data of gait, speech, and drawing for classification of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis 84 : 315-327, 2021
PubMed
10) Sverdrup K, Selbaek G, Bergh S et al : Physical performance across the cognitive spectrum and between dementia subtypes in a population-based sample of older aduhs : the HUNT study. Arch Gerontol Geriatr 95 : 104400, 2021
 
11) Del Campo N, Payoux P, Djilali A et al : Relationship of regional brain Aβ to gait speed. Neurology 86 : 36-43, 2016
 
12) Dao E, Hsiung GR, Sossi V et al : Cerebral Aβ deposition is associated with impaired gait speed and lower extremity function. J Alzheimers Dis 71 : S41-S49, 2019
 
13) Oulhaj A, Wilcock GK, Smith AD et al : Predicting the time of conversion to MCI in the elderly : role of verbal expression and learning. Neurology 73 : 1436-1442, 2009
PubMed
14) Hall AO, Shinkawa K, Kosugi A et al : Using tablet-based assessment to characterize speech for individuals with dementia and mild cognitive impairment : preliminary results. AMIA Jt Summits Transl Sci Proc 2019 : 34-43, 2019
PubMed
15) Yamada Y, Shinkawa K, Shimmei K : Atypical repetition in daily conversation on different days for detecting Alzheimer disease : evaluation of phone-call data from regular monitoring service. JMIR Ment Health 7 : e16790, 2020
PubMed
16) Yamada Y, Shinkawa K, Kobayashi M et al : Tablet-based automatic assessment for early detection of Alzheimer's disease using speech responses to daily life questions. Front Digit Health 3 : 653904, 2021
PubMed
17) Plamondon R, O'Reilly C, Galbally J et al : Recent developments in the study of rapid human movements with the kinematic theory : applications to handwriting and signature synthesis. Pattern Recognit Lett 35 : 225-235, 2014
 
18) Werner P, Rosenblum S, Bar-On G et al : Handwriting process variables discriminating mild Alzheimer's disease and mild cognitive impairment. J Gerontol B Psychol Sci Soc Sci 61 : P228-P236, 2006
PubMed
19) Muller S, Herde L, Preische O et al : Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer's disease from healthy individuals. Sci Rep 9 : 3543, 2019
PubMed
20) Dahmen J, Cook D, Fellows R et al : An analysis of a digital variant of the trail making test using machine learning techniques. Technol Health Care 25 : 251-264, 2017
PubMed
21) Ishikawa T, Nemoto M, Nemoto K et al : Handwriting features of multiple drawing tests for early detection of Alzheimer's disease : a preliminary result. Stud Health Technol Inform 264 : 168-172, 2019
 
P.137 掲載の参考文献
1) Umeda-Kameyama Y, Kameyama M, Kojima T et al : Cognitive function has a stronger correlation with perceived age than with chronological age. Geriatr Gerontol Int 20 : 779-784, 2020
 
2) Christensen K, Thinggaard M, McGue M et al : Perceived age as clinically useful biomarker of ageing : cohort study. BMJ 339, b5262, 2009
PubMed
3) Nielsen BR, Linneberg A, Christensen K et al : Perceived age is associated with bone status in women aged 25-93 years. Age (Dordr) 37 : 106, 2015
PubMed
4) Kido M, Kohara K, Miyawaki S et al : Perceived age of facial features is a significant diagnosis criterion for age-related carotid atherosclerosis in Japanese subjects : J-SHIPP study. Geriatr Gerontol Int 12 : 733-740, 2012
 
5) Umeda-Kameyama Y, Kameyama M, Tanaka T et al : Screening of Alzheimer's disease by facial complexion using artificial intelligence. Aging (Albany NY) 13 : 1765-1772, 2021
PubMed
P.143 掲載の参考文献
1) Guzman-Martinez L, Maccioni RB, Farias GA et al : Biomarkers for Alzheimer's disease. Curr, Alzheimer Res 16 : 518-528, 2019
PubMed
2) Takahashi K, Tanabe K. Ohnuki M et al : Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 : 861-872, 2007
PubMed
3) Inoue H, Nagata N, Kurokawa H et al : iPS cells : a game changer for future medicine. EMBO J 33 : 409-417, 2014
PubMed
4) Hardy J, Selkoe DJ : The amyloid hypothesis of Alzheimer's disease : progress and problems on the road to therapeutics. Science 297 : 353-356, 2002
PubMed
5) Perrin RJ, Fagan AM, Holtzman DM : Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461 : 916-922, 2009
 
6) Mouse Genome Sequencing Consortium, Waterston RH, Lindblad-Toh K et al : Initial sequencing and comparative analysis of the mouse genome. Nature 420 : 520-562, 2002
PubMed
7) Zerbino DR, Achuthan P, Akanni W et al : Ensembl 2018. Nucleic Acids Res 46 : D754-D761, 2018
PubMed
8) Young JE, Boulanger-Weill J, Williams DA et al : Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 16 : 373-385, 2015
PubMed
9) Wang C, Najm R, Xu Q et al : Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector. Nat Med 24 : 647-657, 2018
PubMed
10) Zhao J, Davis MD, Martens YA et al : APOEε4/ε4 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum Mol Genet 26 : 2690-2700, 2017
 
11) Huang Y-WA, Zhou B, Wernig M et al : ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion. Cell 168 : 427-441.e21, 2017
 
12) Sanchez-Danes A, Richaud-Patin Y, Carballo-Carbajal I et al : Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 4 : 380-395, 2012
PubMed
13) Kondo T, Asai M, Tsukita K et al : Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell 12 : 487-496, 2013
 
14) Choi SH, Kim YH, Hebisch M et al : A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515 : 274-278, 2014
PubMed
15) Gonzalez C, Armijo E, Bravo-Alegria J et al : Modeling amyloid beta and tau pathology in human cerebral organoids. Mol Psychiatry 23 : 2363-2374, 2018
PubMed
16) De Strooper B, Karran E : The cellular phase of Alzheimer's disease. Cell 164 : 603-615, 2016
PubMed
17) Kim YH, Choi SH, D'Avanzo C et al : A 3D human neural cell culture system for modeling Alzheimer's disease. Nat Protoc 10 : 985-1006, 2015
PubMed
18) Lancaster MA, Renner M, Martin CA et al : Cerebral organoids model human brain development and microcephaly. Nature 501 : 373-379, 2013
PubMed
19) Kadoshima T, Sakaguchi H, Nakano T et al : Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. Proc Natl Acad Sci U S A 110 : 20284-20289, 2013
PubMed
20) Raja WK, Mungenast AE, Lin YT et al : Self-organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer's disease phenotypes. PLoS One 11 : e0161969, 2016
 
21) Suong DNA, Imamura K, Inoue I et al : Induction of inverted morphology in brain organoids by vertical-mixing bioreactors. Commun Biol 4 : 1213, 2021
PubMed
22) Lin YT, Seo J, Gao F et al : APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes in human iPSC-derived brain cell types. Neuron 98 : 1141-1154.e7, 2018
 
23) Saito T, Matsuba Y, Mihira N et al : Single app knock-in mouse models of Alzheimer's disease. Nat Neurosci 17 : 661-663, 2014
PubMed
24) Yahata N, Asai M, Kitaoka S et al : Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer's disease. PLoS One 6 : e25788, 2011
 
25) Liu Q, Waltz S, Woodruff G et al : Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol 71 : 1481-1489, 2014
 
26) Mertens J, Stuber K, Wunderlich P et al : APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based γ-secretase modulation. Stem Cell Reports 1 : 491-498, 2013
 
27) Vincent F, Loria P, Pregel M et al : Developing predictive assays : the phenotypic screening "rule of 3". Sci Transl Med 7 : 293ps15, 2015
PubMed
28) Lee G, Ramirez CN, Kim H et al : Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 30 : 1244-1248, 2012
PubMed
29) Kondo T, Imamura K, Funayama M et al : iPSC-based compound screening and in vitro trials identify a synergistic Anti-Aβ combination for Alzheimer's disease. Cell Rep 21 : 2304-2312, 2017
 
30) Bright J, Hussain S, Dang V et al : Human secreted tau increases Aβ production. Neurobiol Aging 36 : 693-709, 2015
 
31) Imamura K, Izumi Y, Watanabe A et al : The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci Transl Med 9 : eaaf3962, 2017
 
32) Wainger BJ, Kiskinis E, Mellin C et al : Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep 7 : 1-11, 2014
PubMed
33) Fujimori K, Ishikawa M, Otomo A et al : Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med 24 : 1579-1589, 2018
PubMed
34) Hino K, Horigome K, Nishio M et al : Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J Clin Invest 127 : 3339-3352, 2017
PubMed
35) Hosoya M, Fujioka M, Sone T et al : Cochlear cell modeling using disease-specific iPSCs unveils a degenerative phenotype and suggests treatments for congenital progressive hearing loss. Cell Rep 18 : 68-81, 2017
PubMed
36) Kondo T, Banno H, Okunomiya T et al : Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study : randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. BMJ Open 11 : e051343, 2021
 

書評

最近チェックした商品履歴

Loading...